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Canine idiopathic sebaceous adenitis (ISA) is an inflammatory reaction of sebaceous glands, 
potentially resulting in their complete loss. It is considered a T-cell mediated disease, but its 
precise pathogenesis is still unknown. Topical treatment is an effective but laborious 
treatment. Ciclosporin A (CsA) has recently been shown to ameliorate the clinical picture of 
ISA. It is, however, an expensive treatment option.  
The objective of this multicentre, partially double-blinded, randomized controlled study was 
to evaluate the efficacy of CsA, either alone or with topical therapy, in comparison to topical 
treatment alone, as measured by the primary end-points alopecia and scaling, and multiple 
histological secondary objectives.  
34 dogs with an established diagnosis were treated for 4-6 months and were evaluated before, 
during and after therapy. Both CsA and topical therapy demonstrated efficacy in this study. 
Differences between the treatment protocols were marginal. Topical treatment, both alone and 
in combination with CsA, appeared to reduce scaling more effectively than CsA alone. Both 
therapies reduced alopecia. There is evidence of a synergistic benefit on both scaling and 
alopecia, if both treatment options are combined. Inflammation of the sebaceous glands is also 
best reduced by a combination of both CsA and topical therapy. There is evidence that 
regeneration of sebaceous glands is best achieved by CsA, either given alone or in 
combination with topical treatment. 
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A multicentre placebo-controlled clinical trial on the efficacy of oral ciclosporin A in the 
treatment of canine idiopathic sebaceous adenitis in comparison with conventional 
topical treatment 
 
 
Introduction 
 
Idiopathic sebaceous adenitis (ISA) is an inflammatory reaction of sebaceous glands that can 
lead to their complete destruction.1 ISA is an uncommon dermatosis in dogs, and has been 
rarely reported in other mammals.2-5 Although it can affect any breed, a strong breed 
predisposition has been proposed for the akita, standard poodle, vizsla, samoyed, chow chow, 
hovawart and recently the springer spaniel.6 An autosomal recessive mode of inheritance has 
been suggested in the akita and standard poodle. Clinical signs of ISA usually first appear in 
young to middle-aged dogs. There is no apparent sex predilection.4,5 The clinical features of 
ISA vary between different breeds, but they always comprise silvery-white or yellow-brown 
epidermal scales, and scales that are adherent to the hair shafts (follicular casts). 
 
The clinical disease differs in long-coated versus short-coated dog breeds.4,5 In the former, the 
lesions tend to be symmetric multifocal alopecia2 (probably induced by broken hair shafts) 
associated with scaling and a dull and brittle hair coat.7-9 Lesions start at the head, the pinnae, 
the dorsal neck and the tail and can extend to the dorsal midline. In short-coated dogs, lesions 
tend to be more arciform,5 with coalescing areas of alopecia and fine non-adherent scaling 
that is present predominately on the trunk.10-12 ISA in dogs is non-pruritic unless there is a 
secondary bacterial pyoderma. Histopathological findings in ISA are variable in terms of 
severity, and their character changes in association with chronicity of the disease.7,13,14,15 
 
ISA is commonly unresponsive to treatment with anti-inflammatory doses of 
glucocorticoids.2,10 Synthetic retinoids have been used for their anti-inflammatory properties, 
their effects on keratinocyte differentiation, and their inhibitory effect on sebaceous gland 
activity.11,12,16,17 Isotretinoin has been reported to be effective in vizslas.11 A more than 50% 
reduction in clinical signs was seen in 47% and 52% of dogs treated with isotretinoin or 
etretinate respectively, but outcome was unpredictable.12 Since etretinate is no longer 
commercially available, acitretin is being considered as an alternative. Various nutritional 
supplements with essential fatty acids at high dosages seem to ameliorate clinical signs.3,18,19 
Treatment is currently largely restricted to antiseborrheic shampoos, emollient rinses and 
humectants. They have been useful for partial control of the scaling, but full recovery is often 
not obtained, and the treatment protocol is very labour intensive for the owner.4, 6, 9, 10, 18 
Ciclosporin A (CsA) has shown promising results in the therapy of ISA.9,10,18,20 In a pilot 
study, sole therapy with CsA significantly reduced the inflammation and improved the clinical 
presentation by 60%.20 
 
The objective of this clinical study was to compare the efficacy of oral ciclosporin A in the 
treatment of ISA in the dog when used alone and when used in combination with conventional 
topical therapy, as measured by the primary end-points alopecia and scaling, and 
histopathological secondary objectives.  
 
 
 
 
 
 
 2
Materials and methods 
 
Study design  
The study was designed as a multicentre, randomized, partly double-blinded, placebo-
controlled clinical trial. Owners and investigators were aware of the group of dogs that 
received ciclosporin A as a sole therapy. In the groups where topical treatment was added 
either to ciclosporin A or placebo, neither was aware of the treatment. Therapy was dispensed 
by mail by a person who randomized the dogs. All owners gave written informed consent for 
their dogs to be entered in this trial. 
This clinical study was not designed as a pivotal regulatory trial and was not conducted under 
“Good Clinical Practice” (GCP). Nevertheless, it followed many of the GCP principles, 
including definition of primary and secondary end-points, and written owner consent. The 
study followed a previous pilot study.20 The primary end-point was reached when an 
improvement of at least 46% (moderate effect) in alopecia or scaling was observed after a 
treatment period of 4 months. Sample sizes were ten or 12 dogs per group, and were sufficient 
to detect the above-mentioned differences in primary objectives between study groups. 
 
Cases 
Before entering the study, ISA was confirmed by clinical examination and histopathology, 
fulfilling the widely published criteria for the diagnosis of ISA.2,9,14,21 Briefly, the clinical 
picture of ISA is characterized by a general dull and brittle hair coat often associated with 
hypotrichosis and alopecia.4,5,21 Typically, scales adhere firmly to the hair shafts and are 
called “follicular casts”. A secondary pyoderma may lead to folliculitis and furunculosis 
accompanied by pruritus and occurs mostly in akitas and springer spaniels.6,9 Skin lesions in 
the vizsla tend to be more arciform with coalescing areas of alopecia and fine non-adherent 
scaling.11 Histopathological findings in ISA are variable in terms of severity, and their 
character changes in association with chronicity of the disease.14,15 The most common finding 
is a nodular, granulomatous to pyogranulomatous inflammatory reaction at the isthmus level, 
obscuring the sebaceous glands. Sebocytes are destroyed and may no longer be detectable in 
histological sections. Often a marked orthokeratotic hyperkeratosis is detectable within the 
follicular infundibulum. In advanced stages of the disease, sebaceous glands are completely 
destroyed and inflammatory reactions become sparse.  
 
Varying dermatological procedures to exclude differential diagnoses such as dermatophytosis, 
demodicosis, infectious pyogranulomas, and leishmaniasis were conducted individually by 
each clinician as necessary for the corresponding case. Dogs with a secondary bacterial 
folliculitis were treated with cefalexin (25 mg/kg, twice daily) until cytologically and 
clinically cured, before entering the study. 
 
Treatment 
Dogs were randomly assigned to one of three treatment groups (Figure 1), as follows. 
 
1) The group “CsA” was treated with 5 mg/kg/day of ciclosporin A (Atopica®, Novartis 
Animal Health, Basel, Switzerland). 
2) The group “CsA/Top” was treated with 5 mg/kg/day of ciclosporin A (Atopica®) and was 
simultaneously washed with sulphur/salicylic acid (Sebolytic®, Virbac Animal Health, 
Carros, France) or ethyl lactate (Etiderm®, Virbac Animal Health) and treated with baby oil 
soaks and 70% propylene glycol in water. 
3) The group “Placebo/Top” was treated with placebo capsules identical to CsA once a day 
and was simultaneously washed with sulphur/salicyclic acid (Sebolytic®, Virbac Animal 
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Health) or ethyl lactate (Etiderm®, Virbac Animal Health) and treated with baby oil soaks 
and 70% propylene glycol in water. 
 
The topical treatment (Top) consisted of a shampoo, containing either a combination of 
sulphur and salicylic acid or ethyl lactate. The shampoo was left on for a minimum of 10 min 
to remove scales and was then rinsed off. Thereafter, generic baby oil (e.g. BeBe baby oil, 
Nestle, Frankfurt, Germany) was applied on the whole body and left on for up to 2 h before it 
was washed off with one of the aforementioned shampoos. After the shampoo was rinsed off, 
a mixture off 70% propylene glycol in water was used topically as a spray on affected areas. 
In the early weeks of therapy, this procedure was applied as often as three times a week, but 
not less than once a week. The 70% propylene glycol mixture was sprayed onto affected 
areas, as needed. As soon as an improvement was achieved, the interval between the baby oil 
soaks was increased. 
 
No other treatment was allowed. If clinical improvement was seen after 4 months, the dose of 
CsA or the placebo was reduced to every other day for another 2 months. If no clinical 
improvement was noted, therapy was continued daily for another 2 months.   
        
Randomization 
All dogs were allocated to one of the three treatment groups according to an independently 
established randomization list. Randomization was balanced every three cases. Five dogs 
were not randomized, since no placebo was available at that point in time. Within this group 
of five dogs, three were allocated to the CsA/Top group and two dogs to the CsA group 
(Figure 1). 
 
Clinical evaluation 
To determine clinical improvement under therapy, scaling, alopecia and folliculitis (the latter 
being characterized by focal erythema and papules) were subjectively evaluated and graded 
(0, absent; 1, mild; 2, moderate; and 3, severe) at 22 different body regions. Scaling, alopecia 
and folliculitis were considered mild if these clinical features were visible only with close 
inspection and not easily noticed by the owner. Scaling, alopecia and folliculitis were 
considered moderate if these clinical features were visible by the investigator and possibly 
noticed by the owner. Scaling, alopecia and folliculitis were considered severe if these clinical 
features were easily noticed by the owner. The sum of scores at 22 body regions resulted in a 
total alopecia score, a total scaling score and a total folliculitis score for each patient. The 
maximum final total score was a possible 66 points.  
 
A clinical evaluation was performed at three time points in the study: before treatment, after 4 
months of treatment and after 6 months of treatment. Skin cytology was performed whenever 
a skin infection, either by bacteria or malassezia was suspected. 
 
Histopathological evaluation 
In addition to the above-mentioned clinical investigation, treatment-related changes were also 
determined by histopathological examination of skin biopsy specimens. At least two 6-8 mm 
punch biopsies were taken from clinically affected areas of the body before treatment. After 4 
months of treatment, skin biopsies (same size as before) were obtained from each patient at 
the same initial body area site. Biopsy specimens from patient no. 3 before treatment and from 
patient no. 18 after 4 months of therapy were subsequently lost and could not be included in 
further analysis. 
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Figure 1 Flow chart describing progress of patients through the trial. 
 
 
Tissues were processed routinely, embedded in paraffin and sectioned at approximately 5 μm 
thickness. Sections were stained with haematoxylin and eosin and were evaluated under a 
light microscope. All biopsy specimens were independently assessed in a blinded manner by 
three of the authors (J.L., M.L., and L.M.). Discrepancies in the histopathological evaluation 
were resolved in a pathology working group consisting of these three evaluators. Biopsies 
were considered diagnostic for ISA based on published morphological criteria.2,9,14,21                                       
 
In each tissue section, the number of hair follicles with and without sebaceous glands and the 
number of hair follicles with and without perifollicular inflammation at the isthmus level was 
assessed, resulting in a sebaceous gland score (i.e. percent of hair follicles with sebaceous 
glands) and an inflammation score (i.e. percent of hair follicles with perifollicular 
inflammation). On average, six hair follicles were present in each section. All sections 
showed mostly longitudinal cuts of hair follicles and were sufficient to evaluate the presence 
of sebaceous glands. 
 
Definition of primary and secondary end-points, and statistical analyses 
Primary objectives were alopecia and scaling. These objectives had already been used in a 
pilot study, where they had been shown to be suitable to evaluate the clinical efficacy of 
therapeutic regiments in canine ISA.20 The primary end-point was reached, when an 
improvement of at least 46% (defined as a moderate effect by clinical relevance) in alopecia 
or scaling were observed after a treatment period of 4 months. The folliculitis score was not 
included in further analysis of treatment efficacy, since its standard deviation was extremely 
high (based on the fact that it only occurred in a few dogs) and the sample size did not provide 
sufficient power to detect differences in this parameter. 
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Secondary objectives were evaluated by histopathology. The percentage of hair follicles with 
sebaceous glands (sebaceous gland score) and the percentage of hair follicles with 
perifollicular inflammation (inflammation score) were evaluated as mentioned above.  
 
Demographic and baseline data were compared between groups using nonparametric 
statistics. Baseline clinical and histopathological data was analyzed with an analysis of 
variance (ANOVA). Clinical data, measured at two different treatment time points, were 
analyzed using a repeated-measurements analysis of covariance (RMANCOVA) with the 
parameters treatment group, baseline value, time, and treatment٭time interaction. 
Histopathological data, measured at one treatment time point only, was analyzed using an 
analysis of covariance (ANCOVA) model, with treatment group and baseline value as 
parameters. Pairwise comparison of treatment groups was conducted as linear contrasts. Since 
the scale for clinical scores is not numeric but rather ordinal, this data was analyzed using a 
generalized linear model, in which the log odds of having a higher score are modelled as 
linear functions of the model parameters, i.e. treatment group, time, treatment٭time 
interaction, body region, baseline value and a random effect for each subject. To assess a 
possible relationship between the change over time for different variables, rank correlations 
were calculated for the log change of the two clinical and the two histopathological scores. To 
avoid division by zero or calculating the log of zero, “1” was added to all values before 
dividing and calculating the log. Values of P≤0.05 were considered significant. A comparison 
to baseline (month 0) was not possible as the baseline data entered the model only as 
covariates.  
 
The statistical software program SAS® (Institute Inc., Carry, NC, USA), version 9.1.3. was 
used for ANOVA, ANCOVA and RMANCOVA. For the generalized linear model the SAS 
procedure GLIMMIX was used. 
 
Results 
 
Four investigators from Germany and three investigators from Switzerland recruited a total of 
34 dogs with ISA over a period of 3 years (Figure 1). The 34 dogs belonged to the following 
breeds: hovawart (n=6), akita inu (n=3), Bernese mountain dog (n=3), German shepherd dog 
(n=2), vizsla (n=2), elo (n=2), mixed-breed dogs (n=5) and one each of the following: 
Australian shepherd, Pekinese, cuvac, Tibetan terrier, Labrador retriever, golden retriever, 
Berger blanc, fox terrier, shih tzu, West Highland white terrier and English springer spaniel. 
The mean age was 7 years, with a range from 3 to 12 years. The sex distribution was ten intact 
male dogs, six castrated males, 13 intact females and five spayed female dogs. The mean 
duration of clinical signs before entering the study was 14 months (2 months to 4 years). Of 
these 34 dogs, 12 were assigned to the CsA group, 12 to the CsA/Top group and ten to the 
Placebo/Top group.  
 
Before treatment, there were no significant differences between groups regarding duration of 
the disease, breed, sex, or age. There was a significantly higher number of neutered male dogs 
in the CsA/Top group (P=0.0474), which was considered to have no relevance for the study. 
 
Analysis of the 22 different body regions that were examined for alopecia and scaling 
revealed that locations such as head, ears, neck, dorsal rump/back, flank/thighs and tail were 
most frequently affected, whereas locations such as thorax, abdomen, limbs and paws were 
not or rarely affected. 
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Scaling  
Before treatment, mean total scores for scaling were similar between the three study groups 
(CsA versus CsA/Top, P=0.3080; CsA versus Placebo/Top, P=0.5704; CsA/Top versus 
Placebo/Top, P=0.1285). After 4 months of treatment the mean scaling score at baseline in 
the groups CsA, CsA/Top and Placebo/Top (24.75, 29.83, and 21.80, respectively) decreased 
to 17.67, 8.92, and 11.40, respectively (Figure 2). Improvement in scaling ranged from 29% 
and 48% in the CsA group and in the Placebo/Top group, respectively, to 70% improvement 
in the CsA/Top group. Thus, only the Placebo/Top and the CsA/Top group reached the 
primary end-point. 
A statistical evaluation of this obvious decline was not conducted, since the baseline data 
could only be used as covariates in the employed general linear model. A statistical 
comparison between treatment groups demonstrated that the CsA/Top group improved more 
than the CsA group at month 4 (P=0.0014) and month 6 (P=0.0016), while there were no 
statistical differences when comparing CsA versus Placebo/Top and CsA/Top versus 
Placebo/Top (Table 1). The overall estimated odds ratio for comparison of the CsA/Top group 
and the CsA group was 0.18, which means that the odds of having any particular scaling score 
was 0.18 times lower in the CsA/Top group than in the CsA group (Table 1). In the CsA/Top 
group, a statistically significant improvement was found comparing scaling at month 6 versus 
scaling at month 4 (P=0.0476), while this was not the case for the other two groups (Table 2).        
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Figure 2 
Box plots comparison of the scaling score over time in the three treatment groups. Each box 
goes from the lower quartile to the upper quartile, with a horizontal line at the median; 
whiskers extend from the minimum to the maximum. A plus sign marks the mean value. # = 
p0.05; ## = p0.01. 
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Odds Ratios (S.E.) P-values for comparison                     
Response   Month CsA/Top   vs CsA 
Placebo/Top   
    vs CsA        
Placebo/Top 
vs CsA/Top
CsA/Top 
vs CsA 
Placebo/Top 
vs CsA 
Placebo/Top
vs CsA/Top
overall 0.18 (0.10) 0.47 (0.26) 2.56 (1.45) 0.0014 (B) 0.1755 0.0990 
4 0.20 (0.11) 0.39 (0.22) 1.98 (1.15) 0.0031 (B) 0.1000 0.2429 Scaling 
6 0.17 (0.10) 0.56 (0.35) 3.31 (2.07) 0.0016 (B) 0.3513 0.0566 
overall 0.33 (0.26) 0.21 (0.19) 0.65 (0.60) 0.1610 0.0886 0.6371 
4 0.33 (0.27) 0.55 (0.47) 1.65 (1.45) 0.1738 0.4810 0.5668  Alopecia 
6 0.33 (0.27) 0.08 (0.09) 0.25 (0.29) 0.1769 0.0268 (T) 0.2283 
 
 
Table 1 
Generalized linear models for clinical data show estimates and standard errors for odds ratios 
between each pair of groups, and p-values for the pairwise comparison of groups, overall (i.e. 
averaged over months four and six) and separately for each month. Next to each significant p-
value, the group (B=CsA/Top, T=Placebo/Top) with the smaller scores is printed. 
 
 
 
Odds Ratios (S.E.) P-values for comparison Response Treatment 
6 vs 4 month 6 vs 4 month 
all 0.79 (0.12) 0.1227 
CsA 0.73 (0.16) 0.1464 
CsA/Top 0.63 (0.15) 0.0476 (6) Scaling 
Placebo/Top 1.05 (0.36) 0.8804 
all 0.37 (0.11) 0.0008 (6) 
CsA 0.70 (0.19) 0.1934 
CsA/Top 0.69 (0.22) 0.2343 Alopecia 
Placebo/Top 0.11 (0.08) 0.0042 (6) 
 
 
Table 2 
Generalized linear models for clinical data show estimates and standard errors for odds ratios 
between each pair of groups, and p-values for comparison of month six with month four. Next 
to each p-value, the month with the smaller score is printed. 
 
 
Alopecia 
Before treatment, mean total scores for alopecia were similar between the three study groups 
(CsA versus CsA/Top, P=0.7034; CsA versus Placebo/Top, P=0.7647; CsA/Top versus 
Placebo/Top, P=0.9490). In the groups CsA, CsA/Top and Placebo/Top, the mean alopecia 
score at baseline (16.25, 16.75, and 17.90, respectively) decreased after 4 months of treatment 
to 7.17, 3.25, and 7.70, respectively (Figure 3). A statistical evaluation of this obvious decline 
in alopecia, which was in the range of 57% to 81% (i.e. primary end-point reached in all three 
groups), was not conducted, since the baseline data could only be used as covariates in the 
employed general linear model. A statistical comparison between treatment groups 
demonstrated that none of the treatment groups was superior to another after 4 months of 
therapy (Table 1). At month 6, the mean alopecia score of the Placebo/Top group was 
statistically significantly lower than the mean alopecia score of the CsA group (P=0.0268). 
However, there was no statistical difference between the CsA group and the CsA/Top group 
and none between the CsA/Top group and the Placebo/Top group (Table 1). Only in the 
Placebo/Top group was a statistically significant improvement found between month 6 and 
month 4 (P=0.0042) (Table 2). 
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Figure 3 
Box plots comparison of the alopecia score over time in the three treatment groups. Each box 
goes from the lower quartile to the upper quartile, with a horizontal line at the median; 
whiskers extend from the minimum to the maximum. Values lying more than 1.5 times the 
interquartile distance (which is upper quartile minus lower quartile) away from the box are 
displayed as asterisks and are not included in the whiskers. A plus sign marks the mean value. 
. # = p0.05; ## = p0.01. 
 
 
Inflammation 
On histopathological examination of biopsy specimens prior to treatment, the number of hair 
follicles with inflammation was similar among all groups (CsA versus CsA/Top, P=0.7460; 
CsA versus Placebo/Top, P=0.5054; CsA/Top versus Placebo/Top, P=0.7250). After 4 months 
of treatment, the inflammation score decreased in all treatment groups (Figure 4). Although 
the CsA/Top group showed the lowest inflammation score, no statistical difference was found 
between the treatment groups (CsA versus CsA/Top, P=0.0690; CsA versus Placebo/Top, 
P=0.8612; CsA/Top versus Placebo/Top, P=0.1066).  
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Figure 4 
Box plots comparison of the inflammation score over time in the three treatment groups. Each 
box goes from the lower quartile to the upper quartile, with a horizontal line at the median; 
whiskers extend from the minimum to the maximum. A plus sign marks the mean value. 
 
 
Sebaceous glands 
All groups had a very low sebaceous gland score, reflecting the absence of sebaceous glands 
from most hair follicles (Figure 5). Prior to treatment, the CsA/Top group showed a 
statistically significantly lower sebaceous gland score than the CsA group (P=0.0206) and was 
also lower than the Placebo/Top group (although not statistically different; P=0.0834). There 
was no statistical difference between the CsA group and the Placebo/Top group (P=0.5552). 
In light of the obvious increase in the sebaceous gland score in all groups, this difference prior 
to treatment is not considered to impair interpretation of the sebaceous gland score. Any 
association with the comparatively high number of neutered male dogs in the CsA/Top group 
and the influence of testosterone on sebaceous glands can only be speculated on.  
 
In the groups CsA, CsA/Top and Placebo/Top, the mean sebaceous gland score at baseline 
(9.03, 1.19, and 9.43, respectively) markedly increased after 4 months of treatment to 39.88, 
20.84, and 19.35, respectively (Figure 5). Statistical evaluation demonstrated that the CsA 
group and the CsA/Top group showed higher levels of sebaceous glands than the Placebo/Top 
group (P=0.0203 and P=0.0290, respectively), while there was no statistical difference 
between the CsA group and CsA/Top group (P=0.9629).  
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Figure 5 
Box plots comparison of sebaceous gland score over the time in the three treatment group. 
Each box goes from the lower quartile to the upper quartile, with a horizontal line at the 
median; whiskers extend from the minimum to the maximum. Values lying more than 1.5 
times the interquartile distance (which is upper quartile minus lower quartile) away from the 
box are displayed as asterisks and are not included in the whiskers. A plus sign marks the 
mean value. # = p0.05. 
 
 
Correlations between clinical and histolopathological scores 
Pairwise rank correlation revealed a statistically significant correlation between the two 
primary objectives scaling and alopecia (P=0.0028). A correlation was also found between 
alopecia and inflammation (P=0.0484).  
 
Dose tapering and discontinuation 
The study protocol allowed an optional discontinuation of therapy after 4 months of 
participation. All 34 patients completed 4 months of therapy and were re-evaluated clinically 
and histopathologically at this point of time. After 4 months of therapy, six owners elected to 
discontinue treatment. Data from these six dogs remained included for intent-to-treat analyses. 
From the CsA group two dogs were withdrawn from the study, one due to the development of 
spontaneous hyperadrenocorticism and one due to apparent inefficacy of therapy. In the 
Placebo/Top group, four dogs were withdrawn, two due to lack of efficacy of therapy and two 
because application of the topical treatment was not feasible for the owner (Figure 1). 
 
If the primary end-point (i.e. at least 46% reduction in scaling or alopecia) was met after 4 
months of treatment, the study protocol allowed a change in dosing from once daily to every 
other day. The dosing regimen of CsA and/or placebo was reduced in all dogs from all 
groups, except for two dogs (both from the CsA group), where there was insufficient response 
to therapy after 4 months.  
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Variations in individual dogs 
In some dogs, the treatment response differed markedly from the mean response in the 
respective treatment group. One patient from each the CsA group and the CsA/Top group 
showed a temporary worsening of alopecia after 4 months of therapy, while alopecia 
improved 2 months later. Two dogs from the CsA group and one patient from the CsA/Top 
group showed a worsening of alopecia between month 4 and 6, despite continuation of 
treatment. With regard to scaling, three dogs (two of the CsA group and one of the 
Placebo/Top group) showed worsening during the first 4 months of therapy and improvement 
thereafter. In one patient of each group, scaling after 6 months of treatment was more severe 
than at baseline, although it had partially resolved after 4 months. One explanation for this 
might be the dose reduction of CsA and the reduced frequency of topical treatment.  
 
Adverse drug events 
Adverse drug events were not reported in the Placebo/Top group, but in ten out of 24 dogs 
receiving CsA (42%). The adverse drug events reported in the CsA group and CsA/Top group 
included vomiting and diarrhoea (n=2), gingival hyperplasia (n=3) and hypertrichosis (n=5). 
           
 
Discussion 
 
The 34 dogs allocated to the three treatment groups showed homogeneity in terms of age, sex, 
breed and duration of disease. The age of onset and duration of signs until final diagnosis was 
similar to what has been described in the literature.4,9,12 Only 28 % of the dogs belonged to 
breeds that are reported to be predisposed to ISA (akita inu, n=3; vizsla, n=2; hovawart, n=6; 
and springer spaniel, n=1).6,9,20 Therefore, no conclusions could be made regarding breed 
responses to therapy. Three cases were Bernese mountain dogs, a breed that is rather common 
in Germany and Switzerland and in which ISA has rarely been described. It is known that ISA 
can actually affect any breed. The lack of inclusion of standard poodle dogs (reported to be 
predisposed to ISA) in this study reflects the overall rarity of this breed in Germany and 
Switzerland. 
 
Since there are no validated and published criteria to determine clinical features of canine ISA 
objectively, a scoring system was invented for the two main clinical features of ISA, namely 
alopecia and scaling.20,21 After it had proven its usefulness in a pilot study,20 the same scoring 
system was employed in the clinical trial reported here. Folliculitis, however, was not a useful 
parameter to evaluate treatment response, because it was inconsistently present in dogs of this 
study. It is known that folliculitis associated with ISA varies between breeds, with the akita 
and the springer spaniel being more seriously affected than other breeds.6,14 These two breeds, 
however, were under-represented in our study.  
One weakness of the study is that the conclusions on the efficacy of topical therapy may be 
limited by the variability in accurateness and frequency applied by owners. Owners were 
instructed to treat their dogs topically at least once a week, but were allowed up to three 
treatments a week. We did not collect data on frequency of topical therapy in individual cases, 
and there was no way to assess owner application techniques. 
 
With regard to the primary end-points, all three treatment protocols were able to reduce 
alopecia and scaling. There was no clear difference between the CsA group and the 
Placebo/Top group, demonstrating that both CsA and topical treatment have largely the same 
clinical effect on ISA. The small statistical difference between the CsA group and the 
Placebo/Top group with regard to alopecia after 6 months of treatment is not considered to be 
meaningful in terms of superiority of treatment. 
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Interestingly, there is evidence of a synergistic benefit, if both treatment options are 
combined, since mean scores for alopecia and scaling of the CsA/Top group were always 
lower than those of the other groups. This is supported by a statistical difference in the scaling 
score after 4 months of therapy. The synergism of topical and systemic treatment on scaling 
could be explained by the different mode of action of these two therapeutic approaches. While 
topical treatment has been reported to reduce the keratinous material around the hair and 
within the hair follicle,18 CsA might reduce scaling by an anagen induction of hair follicles 
and a subsequently increased removal of excessive keratin.22-29 A precise anagen-telogen 
evaluation to support this hypothesis, however, was not performed in this study. 
 
Comparing the scaling and alopecia scores from 4 and 6 months of treatment, a statistically 
significant further improvement was demonstrated for the CsA/Top group in terms of scaling 
and for the Placebo/Top group in terms of alopecia. No statistically significant increase was 
observed between month 4 and 6. It is therefore concluded that, in accordance to previous 
observations,20 most dogs show a marked improvement in clinical signs within 4 months, 
irrespective of the treatment. Further improvement is possible with continuation of therapy, 
but its extent is limited. In most dogs, after 4 months of therapy the disease can be controlled 
by a dose reduction of CsA to every other day and/or a reduction in the frequency of topical 
therapy.  
 
The improvement in primary objectives was confirmed by treatment-related changes in 
secondary parameters, i.e. objectives evaluated by histopathology. Differences in these 
secondary objectives between groups might reflect the differences in the mechanism of action 
between topical therapy and CsA. In all three treatment groups, sebaceous glands were nearly 
absent at the beginning of the study. This is a feature which is commonly observed in 
subacute to chronic ISA.14,15,20 In all groups, mean sebaceous gland scores after 4 months of 
therapy were higher compared to baseline scores. Interestingly, there was a statistically 
significant difference in sebaceous gland scores between the CsA and the Placebo/Top group 
and between the CsA/Top group and the Placebo/Top group. The higher mean sebaceous 
gland score in both CsA groups suggests that CsA allows for better regeneration of sebaceous 
glands than topical treatment, as described by Reichler.9  
 
Perifollicular inflammation (i.e. inflammation involving sebaceous glands) was reduced in all 
treatment groups after 4 months of therapy. In the CsA and the CsA/Top group, this decline in 
inflammation most likely reflects the activity of CsA, which is a known immunomodulator. 
The fact that inflammation resolves most in the CsA/Top group and the fact that there is a 
decline of inflammation in those patients that received placebo and topical treatment only, 
suggest some anti-inflammatory properties of the topical treatment, although its precise mode 
of action is yet unclear.  
 
Topical treatment was not associated with any adverse events. Treatment with CsA was also 
considered safe, since few adverse effects were noted during this study. Adverse effects 
included vomiting and/or diarrhoea, gingival hyperplasia and hypertrichosis. These adverse 
effects have been reported previously31-34 and rarely require withdrawal of the medication. 
Hyperadrenocorticism is not a reported side effect of CsA treatment. Thus, the development 
of hyperadrenocorticism in one patient from the CsA group was not considered to be related to 
the therapy. 
Despite the clear evidence of efficacy of either CsA or topical therapy, some cases are 
refractory to treatment. The reasons for this are unknown. Unresponsiveness could be related 
to the chronicity of disease, particularly in cases where all sebaceous glands have been 
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destroyed prior to the commencement of therapy and where perifollicular inflammation has 
already resolved.20 It is also possible that clinical worsening may be caused by other 
concurrent diseases, such as atopic dermatitis, or by diseases that reduce the compliance to 
treatment (as was seen in one patient from the Placebo/Top group). Some dogs might need 
higher doses of CsA, as is known from other autoimmune diseases.30,31 Additionally, as no 
trough levels were measured, we cannot exclude the possibility that in some dogs variability 
in absorption did not render therapeutic levels. 
 
 
Conclusion 
 
Both CsA and topical therapy have clearly demonstrated efficacy in this study. Differences 
between the treatment protocols are marginal. Topical treatment, both alone and in 
combination with CsA, appears to reduce scaling more effectively than CsA alone. Both 
therapies reduce alopecia. There is evidence of a synergistic benefit on both scaling and 
alopecia, if both treatment options are combined. Inflammation of the sebaceous glands is also 
best reduced by a combination of both CsA and topical therapy. There is evidence that 
regeneration of sebaceous glands is best achieved by CsA, either given alone or in 
combination with topical treatment.  
 
Both treatment options have specific advantages and disadvantages that need to be taken into 
account when a patient is subjected to therapy. Ciclosporin A is frequently considered too 
expensive by owners, while topical treatment is considered too labour intensive by others. 
When owners participating in this study were retrospectively asked about their experience, six 
of 20 that used topical treatment considered this therapy impractical. Two owners even 
discontinued the topical treatment. Therefore, it is merely a question of technical feasibility 
and costs that should determine the first choice for one or the other therapy, with some 
evidence that a combination of both therapies provides further benefit for the patient.  
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